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11.INTRODUCTION
Autoimmune diseases occur in 3–5% of the population (1) as a result of
myriad of genetic and environmental factors that lead to altered immune
reactivity(2,3). The alterations in the immune system initiated by a loss of
immunological tolerance to self-antigens lead to the development of auto
reactive phenomena that can be detected in the peripheral blood
1.1 Auto immunity
Alteration in immune system occurs due to various genetic and
environmental factors leading to development of auto reactive phenomenon by a
loss of immunological tolerance to self-antigens that can be detected in the
peripheral blood in the form of the autoantibodies. The terms used to describe
these diseases collectively include “collagen vascular disease”, “connective
tissue disease”, “autoimmune connective tissue disease” because of their
common autoimmune basis. Defining the specific pathogenic mediators that
may trigger the development or progression of an autoimmune disease remains
a focus of intense research(4).
The autoimmune connective tissue diseases (AI CTDs) are a group of
polygenic disorders often having heterogeneous and overlapping clinical
features. Certain features are common to all of them viz. autoimmunity,
vascular abnormality, arthritis/ arthralgia and cutaneous manifestations(5)
21.2 Connective tissue disorders
Connective tissue diseases (CTDs) are a collection of autoimmune
disorders characterised by antinuclear antibodies (ANAs) in the serum of the
patients. CTDs relevant to dermatology are Systemic Lupus Erythematosus,
drug induced lupus, Scleroderma, Dermatomyositis, Sjogren’s syndrome and
mixed connective tissue diseases. ANAs are autoantibodies directed against
various cell organelles including cytoplasm, nuclei, nucleoli, subcellular
structures and cell surfaces (6)The antigens recognised are mainly proteins and
nucleic acids. These autoantibodies are involved in the pathogenesis of the
disease and also help in diagnosing and treating the disease as well as in
assessing the prognosis of the disease.
1.3 Antinuclear antibodies
ANA are a specific class of autoantibodies that have the capability of
binding and destroying certain structures within the nucleus of the cells. These
antibodies are involved in the disease pathogenesis, and they also constitute the
basis for diagnosis and treatment of CTD(7).
1.3.1 Types of Anti nuclear antibodies
ANA have been categorized into two main groups:
• Autoantibodies to DNA and histones
3• Autoantibodies to extractable nuclear antigens (ENA): Sm, ribonucleoproteins
(RNP), SSA/Ro, SSB/La, Scl-70, Jo-1 and PM1
1.4 Extractable Nuclear Autoantibodies
Extractable Nuclear Autoantibodies to DNA and histones include
antibodies against single and double stranded DNA (ssDNA and dsDNA).
Significant levels of anti-dsDNA antibodies are considered to be confirmatory
in the diagnosis of systemic lupus erythematosus (SLE). Anti-histone antibodies
are indicative of drug induced lupus(8). Besides DNA and histones,
autoantibodies may also target other nuclear antigens. These nuclear antigens
were named extractable nuclear antigens (ENA), as originally they were
extracted from the nuclei with saline solution(9).
1.5 ENAs in Connective Tissue Disorders
(ENAs) Antibodies to Saline-extracted Antigens; Anti-RNP; Anti-
Ribonucleoprotein; Anti-U(1)RNP; Anti-SmRNP; Anti-SSA; SSA (Ro); Anti-
Sjögren Syndrome A; Anti-SSB; SSB (La); Anti-Sjögren Syndrome B; Anti-
Sm; Smith Antibody; Scl-70; Anti-Topoisomerase; Scleroderma Antibodies;
Anti-Jo-1; Antihistidyl Transfer RNA Synthase Antibodies
Although most of these ENA are disease specific, a significant overlap exists.
Sensitivity and specificity may also vary depending upon the type of underlying
CTD. Presence of autoantibodies in the sera of patients constitutes one of the
criteria used for diagnosis of CTD and used to help diagnose and distinguish
4between autoimmune disorders as well as to monitor autoimmune disease
progression. ENA screening tests and profiles can be done using enzyme-linked
immunosorbent assay. If the ENA screen test is positive, an ENA profile test is
done to detect the specific anti- ENA antibody(10,11)
1.6 Significance of ENAs
Detecting antibodies to ENAs involves testing patient’s serum for
antibodies against various specific components of the cell nucleus. The nuclear
antigens are extracted individually, and the patient’s sera is tested against each
one. Seven antibodies are routinely tested for by ELISA. For some antibodies,
further confirmatory testing may be required, (for example, for Jo 1 antibodies),
as false positives may occur with the screening ELISA. Interpretation in the
clinical context is important. It is less likely that a patient will develop clinically
significant autoimmune disease if the ENAs are all negative(12,13).
1.7 ENAs in connective tissue disorders
The incidence of autoimmune connective tissue disorder is increasing day
by day due to availability of modern techniques to detect them in its earlier
stage. From this study it can be emphasized that more than one connective
tissue diseases do exist in patient suspected of having one connective tissue
disorder(14,15). Hence there is need to correlate clinical diagnosis with serological
testing (Anti-ENA profile) so that early diagnosis, intervention and prognostic
outcome of illness can be determined. ELISA-based kits have become the most
5widely used method for anti-ENA antibody testing, This usage is largely due to
their relative simplicity of performance, objectivity in interpretation, rapid
turnaround time, and capacity for automation(16)
1.8 Detection methods of ENAs
The techniques used for detection of specific-ANA includes Enzyme
Linked Immuno Sorbent Assay(ELISA), Crithidia luciliae
Immunofluorescence(CLIF), Farr assay (radio-labelled assay), Counter current
immune electrophoresis(CIE), Passive haem agglutination assay(PHA), Western
blot, Dot blot, Line blot Immunoassay, Multiplex Immunoassay(MIA), Flow
cytometry, Antigen microarray.
1.9 ENA Detection by ELISA
ELISA method is simple to perform, quantitative, and offer high
throughput volume. ELISA is becoming the most widely used method. These
antigen specific ELISA assays react with single autoantigens e.g.  dsDNA, SS-
A/Ro, SS-B/La, Scl-70, Sm, Sm/RNP etc. ELISA has been proven to be a
sensitive and specific detection method, having advantages over
immunodiffusion(17,18), and is becoming widely used. antigen specific assay that
detects ENA and reacts with a single autoantigen i.e. dsDNA, SS-A/Ro, SS-
B/La, Scl-70, Sm, Sm/RNP etc.
6In antigen specific assay multiple antigens are coated on to microtitre
plates, usually a combination of SSA/Ro, SSB/La, Sm, and U1-RNP, with many
also including Jo-1 and Scl70. This new test is both highly specific and sensitive
and substantially decreases the time involved when screening large numbers of
patient samples. The test is simple to perform, can be automated and does not
require highly trained operators who can recognize microscopic patterns.
ELISA is therefore becoming the most widely used method not only for routine
screening but also for detection of specific ENA.
72. AIMS AND OBJECTIVES
 To detect the presence of Extractable Nuclear Antibodies in ANA
positive subjects and ANA negative controls
 To study the different types of  Extractable Nuclear Antibodies (SSA,
SSB, Sm, RNP/Sm, Scl-70,JO-1) present in the  study population
 To find  the  association of  different ENA subtypes in connective tissue
disorders.
83. REVIEW OF LITRATURE
3.1 AUTOIMMUNITY
Normally the function of immune system in our body is to recognize
foreign elements and to destroy these before they could harm us either by
humoral immune response (specific antibody formation) or cell mediated
immune response by activation and clonal expansion of T cells. Thus the
immune system defends the body against infections and certain other diseases
by identifying, attacking, and destroying germs and other foreign substances.
Sometimes the immune system makes a mistake and starts attacking the body’s
own tissues or organs. This is called autoimmunity.(19)
An autoimmune disease is a case of mistaken identity; it is an abnormal
condition in which the body reacts against constituents of its own tissues. The
result may be simple hypersensitivity reaction and or autoimmune disease when
the body begins attacking its own healthy tissues. About 5 % to 7 % of adults
suffer from autoimmune diseases and two thirds of these are females.
3.1.1Effects of Autoimmunity
Autoimmunity may result due to some extraneous environmental factors
like some viral infections and exposure to  some mutagenic agents; can be due
to the breakdown and failure of immune regulation and due to some aberration
in the genes. The result is autoimmune disease which may involve a particular
9organ when it is called an organ specific disease (e.g. Addison’s disease
involving Adrenal glands) or it may involve particular cells/tissues all over the
body  when  it is called non-organ specific or disseminated disease (e.g.
Rheumatoid  arthritis). (3)
3.1.2 Host response to Autoimmunity
Autoimmunity refers to the body’s development of intolerance of the
antigens on its own cells i. e. there is an immune response to one’s own tissue
antigens. This type of body response results in a disease state characterized by a
specific antibody or cell-mediated immune response against the body’s own
tissues (auto antigens). So, we can say that autoimmunity is the breakdown of
mechanisms responsible for self tolerance and induction of an immune response
against components of self. The immunological mechanism of the body is
dependent on two major factors: (1) the inactivation and rejection of foreign
substances and (2) the ability to differentiate between the body’s own antigens
(‘self’) and foreign (‘non self’). It is not yet known exactly what causes the
body to fail to recognize self proteins as its own and to react to them as if they
were foreign resulting in autoimmunity and may be autoimmune disease(21)
3.2 History
A very famous, Nobel laureate Paul Ehrlich (1854-1915) coined the term
“Horror autotoxicus” to emphasize that body has innate aversion to
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immunological self-destruction. “Horror autotoxicus” literally means the horror
of self-toxicity. However, as we now know, the immune system can upon
occasion attack own body and result is autoimmune disorders. The history of
autoimmunity is far from over as autoimmunity is being incriminated in
etiopathogenesis of more and more disease conditions
3.3 IMMUNOLOGICAL TOLERANCE
Immunological tolerance is defined as a state in which the immune
system does not positively respond to autoantigens. The concept of
immunological tolerance for autoreactive T and B cells has been changing
rapidly as new experimental systems have been established.
3.3.1 CENTRAL IMMUNOLOGICAL TOLERANCE
T cells, which play a central role in acquired immunity, undergo clonal
deletion by apoptosis when they are exposed to a sufficient amount of
autoantigens in the thymus where they differentiate. This is called central
tolerance. It has been revealed recently that some molecules previously
considered to be expressed only in a specific organ are also expressed in
medullary epithelial cells of the thymus. This indicates that the thymus is
intended to express as many autoantigens as possible in the body to induce
tolerance for them. However, this mechanism is limited by the fact that not all
autoantigens are expressed in the thymus(21).
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Furthermore, T cells that weakly react with autoantigens can migrate into
peripheral tissue. Each antigen should have multiple amino acid sequences that
can bind to antigen-presenting MHC molecules. These sequences are called
epitopes or antigenic determinants. However, some epitopes are not presented
as antigens under usual conditions probably due to the relationship with other
epitopes or proteolysis in the cells. Such epitopes are called “cryptic
T cells that migrate into peripheral tissues undergo clonal deletion by
apoptosis in the similar way as in the thymus when the stimulus of autoantigens
is strong. When the stimulus is not strong enough, T cells undergo clonal anergy
(clonal paralysis). When the amount of autoantigens is further reduced, T cells
become ignorant (non-tolerant and unresponsive)(21). In this regard, it is
important that naïve T cells circulate only in lymphoid organs without entering
other organs to maintain the state of ignorant
It has also been reported that tolerance may be actively suppressed by
regulatory T cells. Recent studies have reported T cells with various regulatory
functions, including those that produce cytokines with suppressive effects, such
as interleukin (IL)-10 and transforming growth factor (TGF) -βand those that
have CD4₊ and CD25₊surface markers and provide suppressive effect through
cell-cell contact. These various suppressive T cells may play different roles,
depending on the activation of autoreactive T cells.
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B cells have been reported to undergo anergy in response to soluble
autoantigens and clonal deletion in response to stronger autoantigens, such as
those on cell surfaces in the bone marrow where they differentiate. B cells that
strongly react with soluble antigens such as self-molecules at the germinal
center of peripheral tissues are also deleted through apoptosis. B cells have been
reported to cause a phenomenon called receptor editing in which B cells that
react with an autoantigen rearrange the gene of the antigen receptor
(immunoglobulin) once again to make another non-autoreactive receptor(21).
3.3.2Peripheral T cell tolerance mechanisms:
 Immunological Ignorance: Very few self proteins contain peptides that
are presented by a given MHC molecule at a level sufficient for T cell
activation, Autoreactive T cells are present but not normally activated.
 Suppressor or regulatory T cells: mediate active suppression of
autoreactive cells
 Immunologically privileged sites: no lymphatic drainage or non-
vascularized areas; presence of immunosuppressive factors.
3.3.3 Peripheral B cell tolerance mechanisms
 Contact with soluble antigens: this leads to downregulation of surface
IgM, and so there is inhibition of signaling resulting in anergic (non
13
reactive) cells and so no immune response occurs against these soluble
antigens, there is tolerance to these antigens.
 Another mechanism of self tolerance is the Fas-mediated apoptosis
(programmed cell death) of anergic B cell following secondary encounter
with CD4 T cell
3.4 Initiation of Autoimmunity in Autoimmune Diseases
It is generally believed that autoimmunity is triggered by the development
or activation of CD4_ helper T cells that react with a specific autoantigen.
Based on various evidence, it is now proposed that a specific antigenic stimulus
is the first trigger of autoimmunity. This is called the “single initiating antigen
hypothesis”.  For example, molecular mimicry in which immune response
occurs to both an external microbial antigen and an autoantigen because of their
homology is considered one of the mechanisms of initiating autoimmunity(22).
Triggering autoimmunity alone probably results in a transient event
and is insufficient to induce autoimmune disease.The importance of antigen-
specific CD4 cells in pathological autoimmune condition has been suggested
from the association with MHC class II antigens (such as DR antigen of HLA in
humans), infiltration of CD4 cells in many organ-specific autoimmune diseases,
and production of autoantibodies of IgG type. Although various factors are
associated with the progression of autoimmune diseases, one of the important
phenomena is epitope spreading.
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Epitope spreading refers to a phenomenon in which autoantigens
(antigen determinants) detected by T and B cells increase during the process
from the initial activation of autoreactive lymphocytes to the chronic phase.
This concept is important for explaining, for example, the mechanism by which
autoimmune response induced by one cryptic epitope leads to complete
autoimmune response. Both B and T cells are involved in this phenomenon.
Particularly, B cells play an important role as antigen presenting cells for T
cells.(3)
3.4.1 Autoimmune diseases
Autoimmune diseases are rare, but as a group they affect about 5-8 % of
individuals. Autoimmune diseases can be broadly classified into two groups.
First are organ-specific diseases, they are characterized by autoantibodies that
target single or closely related organs. Second is, systemic diseases that is
characterized by variety of autoantibodies directed toward specific collection of
nuclear and intracellular cytoplasm molecules, also called non-organ specific
autoantibodies. Systemic autoimmune diseases are generally characterized by
the product of autoantibodies against nuclear and cytoplasmic antigens and
chronic inflammatory process involving different organs. It is important to get
an early diagnosis and treatment of systemic rheumatic diseases because it
improves remission rates and prognosis. Systemic rheumatic diseases are
diseases such as dermatomyositis, mixed connective tissue disease,
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polymyositis, Sjögren’s syndrome, systemic sclerosis, systemic lupus
erythematosus and few other diseases .(23,24)
3.5 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SLE is a chronic inflammatory systemic autoimmune disease,
characterized by various organ and tissue damage, especially joints, the heart,
lungs, skin, blood and kidneys, which can be hard to diagnose. SLE has an
negative effect on health-related quality of patient life but it can also results in
noticeable morbidity, fatality and disability . Almost all SLE patients have
positive antinuclear antibody test and high concentration of autoantibodies are
common. Antibodies against dsDNA are most frequent but antibodies against
Sm, RNP, SSA/Ro and SSB/La can also be found. Positive ANA screen test and
antibodies against dsDNA and Sm are a part of the criteria for SLE.
A study conducted by Egner, et al 2000; Rahman & Isenberg, 2008 says
that Many drugs cause a variant of lupus called drug-induced lupus, but about
10% of SLE like disease is drug induced and potentially reversible. Patient with
druginduced lupus usually have symptoms like skin and joint manifestation but
rarely renal and neurologic features (25).
3.5.1 EPIDEMIOLOGY
Systemic lupus erythematosus is an infrequent disease that is easily
confused with many other disorders . It is found in approximately 0.04-0.07%
of individuals . It is nine times more common in females.
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3.5.2 Incidence and prevalence in India
SLE is rare in India. A prevalence study in India (carried out in a rural
population near Delhi) found a point prevalence of 3 per 100,000(2) Copcord
Bhigwan study ( an ongoing, prospective population study from Pune) found a
crude incidence rate of 1 per 25,000 person years i.e. 4 per 100,000 population
per year (personal communication). Despite its rarity, SLE has considerable
impact on the patient, her/his family and health services available.
3.5.3 ETIOPATHOGENESIS
The proposed pathogenic mechanisms of SLE are Interactions between
susceptibility genes and environmental factors result in abnormal immune
responses, which vary among different patients. Those responses may include
(1) activation of innate immunity (dendritic cells, monocyte/macrophages) by
CpG DNA, DNA in immune complexes, viral RNA, and RNA in RNA/protein
self-antigens; (2) lowered activation thresholds and abnormal activation
pathways in adaptive immunity cells (T and B lymphocytes); (3) ineffective
regulatory CD4+ and CD8+ T cells; and (4) reduced clearance of immune
complexes and of apoptotic cells. Self-antigens (nucleosomal DNA/protein;
RNA/protein in Sm, Ro, and La; phospholipids) are available for recognition by
the immune system in surface blebs of apoptotic cells; thus antigens,
autoantibodies, and immune complexes persist for prolonged periods of time,
allowing inflammation and disease to develop.
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3.5.4 CLINICAL MANIFESTATIONS
Musculoskeletal Manifestations
Most people with SLE have intermittent polyarthritis, varying from mild
to disabling, characterized by soft tissue swelling and tenderness in joints, most
commonly in hands, wrists, and knees. Joint deformities (hands and feet)
develop in only 10% of patients.
Cutaneous Manifestations
Lupus dermatitis can be classified as discoid lupus erythematosus (DLE),
systemic rash, subcutaneous lupus erythematosus (SCLE), or "other." Discoid
lesions are roughly circular with slightly raised, scaly hyperpigmented
erythematous rims and depigmented, atrophic centers in which all dermal
appendages are permanently destroyed. Lesions can be disfiguring, particularly
on the face and scalp. The most common SLE rash is a photosensitive, slightly
raised erythema, occasionally scaly, on the face (particularly the cheeks and
nose—the "butterfly" rash), ears, chin, V region of the neck and chest, upper
back, and extensor surfaces of the arms. Worsening of this rash often
accompanies flare of systemic disease. Rashes can be minor or severe; they may
be the major disease manifestation. Small, painful ulcerations on the oral or
nasal mucosa are common in SLE; the lesions resemble aphthous ulcers(26).
Renal Manifestations
Nephritis is usually the most serious manifestation of SLE, particularly
since nephritis and infection are the leading causes of mortality in the first
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decade of disease. Patients with dangerous proliferative forms of glomerular
damage (ISN III and IV) usually have microscopic hematuria and proteinuria
(>500 mg per 24 h); approximately one-half develop nephrotic syndrome, and
most develop hypertension
Nervous System Manifestations
The most common manifestation of diffuse CNS lupus is cognitive
dysfunction, including difficulties with memory and reasoning. Headaches are
also common. Psychosis can be the dominant manifestation of SLE; it must be
distinguished from glucocorticoid-induced psychosis.
Vascular Occlusions
Antiphospholipid antibodies are associated with hypercoagulability and
acute thrombotic events, whereas chronic disease is associated with accelerated
atherosclerosis. In SLE, myocardial infarctions are primarily manifestations of
accelerated atherosclerosis. The increased risk for vascular events is seven- to
tenfold overall, and higher in women <45 years old with SLE.
Pulmonary Manifestations
The most common pulmonary manifestation of SLE is pleuritis with or
without pleural effusion. Pulmonary infiltrates also occur as a manifestation of
active SLE and are difficult to distinguish from infection on imaging studies.
Life-threatening pulmonary manifestations include interstitial inflammation
leading to fibrosis, shrinking lung syndrome, and intra-alveolar haemorrhage.
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Cardiac Manifestations
Pericarditis is the most frequent cardiac manifestation. More serious
cardiac manifestations are myocarditis and fibrinous endocarditis of Libman-
Sacks. The endocardial involvement can lead to valvular insufficiencies, most
commonly of the mitral or aortic valves, or to embolic events.
Hematologic Manifestations
The most frequent hematologic manifestation of SLE is anemia, usually
normochromic normocytic, reflecting chronic illness. Hemolysis can be rapid in
onset and severe, requiring high-dose glucocorticoid therapy, which is effective
in most patients. Leukopenia is also common and almost always consists of
lymphopenia, not granulocytopenia; this rarely predisposes to infections and by
itself usually does not require therapy.
Gastrointestinal Manifestations
Nausea, sometimes with vomiting and diarrhea, can be manifestations of
an SLE flare, as can diffuse abdominal pain probably caused by autoimmune
peritonitis and/or intestinal vasculitis.
Ocular Manifestations
Sicca syndrome (Sjögren's syndrome;  and nonspecific conjunctivitis are
common in SLE and rarely threaten vision. In contrast, retinal vasculitis and
optic neuritis are serious manifestations: blindness can develop over days to
weeks.
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3.5.5 DIAGNOSIS
SLE with high titer anti-dsDNA antibodies
High titers of anti-dsDNA are associated with disease activity in SLE. In
the “Euro-Lupus” cohort (27), anti-dsDNA antibodies were associated with a
higher prevalence of nephropathy, hemolytic anemia and fever. In contrast,
patients with high titer anti-dsDNA antibodies have a lower prevalence of
thrombosis and sicca syndrome.
SLE with anti-ENA antibodies
Anti-Ro (SSA) antibodies, often accompanied by anti-La (SSB), are
found in 20 and 30% of SLE patients. The former have been found to be
associated with a higher prevalence of subacute cutaneous lesions and sicca
syndrome, but with a lower prevalence of thrombocytopenia. Anti-La (SSB)
may be associated with malar rash, subacute cutaneous lesions, photosensitivity,
arthritis, serositis, and thrombosis. The prevalence of anti-U1-snRNP was
13%(28).
3.5.6 PROGNOSIS
A study conducted by.Kasitanon N et al (Baltimore) 85:147, 2006 ,The
prognosis of SLE patients has improved significantly over the past 40 years.
The reasons for this improvement are likely multifactorial and include earlier
diagnosis, more effective treatment, and better medical management of such
complications as infection and renal disease(29) . Recognition of long-term
complications of disease plays important role in prognosis(30)
21
3.6 MIXED CONNECTIVE TISSUE DISEASE (MCTD)
MCTD was first described by Sharp et al (1971- 72) as a distinct
syndrome in which the combination of features similar to those of systemic
lupus erythematosus (SLE), systemic sclerosis (SSC),
dermatomyositis/polymyositis and rheumatoid arthritis (RA). The disease was
considered unique as it was associated with autoantibodies to a Ribonuclease –
sensitive component of extractable nuclear antigen (ENA) now known as
U1RNP.
3.6.1 EPIDEMIOLOGY
MCTD is now recognized to occur through out the world. It is
predominantly a disease of females, with female to male ratio of 16:1. (1) The
disease is seen among all age groups range from 4 – 80 years; the mean age of
onset in adult is 35 years and 10 years in children. The incidence was low when
compared with other collagen disease like systemic lupus erythematosus,
dermatomyositis/polymyositis, rheumatoid arthritis and Scleroderma.
3.6.2 ETIOPATHOGENESIS
Gunnarsson et al., 2011; Mahler & Fritzler, 2010 said that, It is a
syndrome with overlapping features between other systemic rheumatic diseases
such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis,
polymyositis and dermatomyositis . Some patients even go on and develop
systemic sclerosis or systemic lupus erythematosus later on.
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3.6.3 CLINICAL FEATURES
The most common skin change is the Raynaud’s phenomenon, which
usually presents early in the course of the disease (31). Skin manifestations may
present as a malar rash, generalized erythematous rash, pigmentation
/depigmentation, chronic discoid lesions (similar to SLE, DM /
PM,Scleroderma). It is characteristically associated with swelling of the hands
particularly fingers (sausage appearance) and the skin may be taut, thick with
occasional telengiectasia. Mucous membrane involvement can include
orogenital and buccal ulcerations, nasal septal perforation, and the sicca
complex.
Fever of unknown origin may be the presenting feature of MCTD (32).
Raynaud’s phenomenon is one of the commonest symptoms seen in 75%-100%
of patients.
Approximately 60 percent of patients with MCTD develop an obvious
arthritis, often with deformities characteristic of rheumatoid disease, such as
boutonniere deformities and swan neck changes(33,34)
Myalgias and myositis can be seen in 30%-50% of patients.
Disordered motility in the upper gastrointestinal tract is the commonest
problem(35). It may present as vasculitis with complications like bowel ischemia,
intestinal perforation and pancreatitis.
Neurological manifestations are seen in 20-30% patients presenting as
aseptic meningitis, trigeminal neuralgia, demyelination, transverse myelitis
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and peripheral neuropathy. The most frequent manifestation is a trigeminal
(fifth cranial) nerve neuropathy.
Right ventricular hypertrophy, right atrial enlargement, and inter-
ventricular conduction defects(36). Pericarditis is the commonest clinical
manifestation of cardiac involvement being reported in 10 to 30 percent of
patients; pericardial tamponade is rare(37).
There is a wide spectrum of pulmonary problems that can occur in
MCTD(38) Pleural effusions ,Pleuritic pain ,Pulmonary hypertension ,Interstitial
lung disease ,Thromboembolic disease ,Alveolar haemorrhage ,Diaphragmatic
dysfunction ,Aspiration pneumonitis/pneumonia ,Obstructive airways disease
,Pulmonary infections ,Pulmonary vasculitis
3.6.4 DIAGNOSIS
MCTD a distinct clinical entity is that the presence of high titers of anti-
U1 RNP antibodies is associated with several distinctive clinical characteristics
3.6.5 PROGNOSIS:
MCTD has relatively good prognosis in view of low prevalence of
serious renal disease and life-threatening neurologic problems. Mortality
associated with MCTD ranges, in different studies, from 16 to 28 percent at 10
to 12 years[ Gendi NS et al1995 Feb;38(2):259-66.]  Morbidity is quite high in
patients with MCTD
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3.7 SJOGREN‘S SYNDROME (SS)
Sjogren’s syndrome (SS) is a chronic inflammatoryautoimmune disease
characterized by mixed cellular infiltration of exocrine glands, notably the
lachrymal glands and salivary glands. (autoimmune exocrinopathy). This
inflammation causes dryness of the eyes, (xerophthalmia), dryness of mouth
(xerostomia) and very frequently dryness of nose, throat and vagina. The
combination of dry eyes and dry mouth is often referred to as sicca syndrome.
In many cases, these clinical features are associated with other autoimmune
diseases(39)
Sjogren‘s syndrome can occur alone as primary (pSS) Primary Sjögren’s
syndrome: comprises the “sicca” syndrome without an associated autoimmune
rheumatic disease. Exocrine function seems to be more severely impaired than
in the secondary type and primary SS is associated frequently with a variety of
extra glandular manifestations. Secondary Sjögren’s syndrome1 consists of a
sicca complex, which may be relatively mild and associated with one of the
autoimmune diseases.or associated with other autoimmune diseases for example
rheumatoid arthritis or systemic lupus erythematosus as secondary SS (sSS) .
3.7.1 EPEDIMIOLOGY
A study conducted by Fox RI,  Sjogren’s syndrome can occur in any age
group, but it affects females than males as in other CTDs (90% of all the
patients). SS occurs in the fourth, fifth and sixth decades of life. Primary SS is
found in approximately 0.1-0.2% of individuals, pSS and sSS together are found
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in approximately 1-3% of individuals and are nine times more common in
females[Alamanos et al., 2006; Salliot et al., 2007; Vitali et al., 2002]
3.7.2 ETIOPATHOGENESIS
Sjogren's syndrome is considered an autoimmune disease characterized
by chronic inflammation involving the exocrine glands. A widely accepted
model of the pathogenesis of Sjögren's syndrome is that in genetically
predisposed individuals (reviewed by Harley in this issue), various
environmental factors such as viral infections lead to epithelial cell activation
and a protracted inflammatory response with features of systemic
autoimmunity.
3.7.3 CLINICAL FEATURES
Sjogren’s syndrome is associated with a wide variety of clinical features.
Patients frequently complain of their eye feeling dry, sore and gritty. They may
have difficulty in wearing contact lenses and cutting onions no longer induces
tears. Complications of untreated sicca syndrome results in corneal ulceration,
and perforation, leading to uveitis, cataract and glaucoma.
All patients with Sjögren’s syndrome complain of dryness of mouth, lip
cracking, difficulty in mastication, and at times dysphagia. Drying of tongue
and absence of salivary pool can cause angular stomatitis, fissuring and
ulceration of the tongue, dental caries and candidiasis. Sialography is a radio-
contrast method of assessing anatomical changes in the salivary duct system.
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3.7.4 PROGNOSIS
Prognosis is generally good unless the condition is part of an associated
disorder. There is, however, considerable morbidity. Patients with a low C4
count have a high risk for development of non-Hodgkin's lymphoma and have a
worse prognosis with higher mortality rates
3.8 SCLERODERMA/SYSTEMIC SCLEROSIS (SSC)
Scleroderma is an autoimmune disorder of unknown etiology,
characterized by fibrosis and microvascular injury in affected organs. The
hallmark of the disease is thickening and tightness of the skin and of
subcutaneous tissue. Scleroderma may be confined to the skin (localized) or it
may be generalized (systemic sclerosis). In generalized involvement virtually all
organ systems can be involved, most importantly the skin, blood vessels, lungs,
kidneys, gastrointestinal tract, and the heart. Systemic sclerosis is further
subdivided into limited and diffuse variants depending on the extent of
cutaneous involvement
3.8.1 EPIDEMIOLOGY
It is characterized by fibrosis in the skin and internal organs and is found
in approximately 0.0013-0.014% of individuals. It is ten times more common in
females . SSc is associated with increased mortality but the prognoses are
highly variable.
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3.8.2 ETIO PATHOGENESIS
A comprehensive view of the pathogenesis of SSc must incorporate the
three cardinal features of the disease: (1) vasculopathy, (2) cellular and humoral
auto immunity, and (3) progressive visceral and vascular fibrosis in multiple
organs.
3.8.3 CLINICAL FEATURES
Raynaud’s phenomenon is usually the initial symptom of scleroderma,
either with or without puffiness of fingers. This is often accompanied by
fatigue, early morning stiffness and musculoarticular pain. Up to 25% of
patients may be initially mistaken for rheumatoid arthritis (RA). The hallmark
of scleroderma is taut, hidebound skin, which may take several years to
develop.
3.8.4 DIAGNOSIS
Anti-Ro antibodies do occur in patients with SSc, but at a lower
frequency than in those with SLE or Sjogren syndrome (less than 35%) .
However, Sjögren syndrome has been described in up to 20% of all patients
with SSc, with about one-third to one-half of those with anti-Ro antibodies.
Sjögren syndrome is actually associated with about 35% of SSc patients
positive for anti-Ro.
3.8.5 Prognosis
The prognosis in scleroderma is highly dependent on the extent of major
organ disease. Patients with limited scleroderma have a normal life expectancy
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with approximately a 90% 5-year survival rate. Patients with diffuse skin
disease have about a 70–80% 5-year survival rate.
3.9 POLYMYOSITIS AND DERMATOMYOSITIS (PM/DM)
Polymyositis (PM) and dermatomyositis (DM) are chronic idiopathic
inflammatory myopathies. It is a long term inflammatory disorder which
affects muscles.
3.9.1 EPIDEMIOLOGY
The annual incidence of DM/PM ranges from 2 to 10 new cases per
million persons. Bimodal distribution occurs with peaks between ages 10 and 15
years in children and between ages 45 and 60 years in adults. Theincidence is
higher in women in comparison with men (2.5:1). The average age of onset of
PM/DM without malignancy appears to be around fifth and sixth decades. PM
mostly affects individuals over 20 years of age. It is two times more common in
females than males. DM affects individuals of all ages
3.9.2 ETIOPATHOGENESIS
DM is widely accepted to be of autoimmune origin. Although
autoantibodies are found in most patients, most are not myositis-specific, and
their role in the pathogenesis is uncertain. Much about the pathogenesis is
unclear, but it is postulated that DM is predominantly humourally mediated and
that the endothelium of endomysial capillaries is the primary antigenic target.
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3.9.3 CLINICAL FEATURES
In most cases, the first symptom is a distinctive skin rash on the face,
eyelids, chest, nail cuticle areas, knuckles, knees or elbows.
Other symptoms : muscle pain, muscle tenderness , problems swallowing, lung
problems, hard calcium deposits underneath the skin, which is mostly seen in
children, fatigue, unintentional weight loss, fever
3.9.4 PROGNOSIS
Mortality remains 2-3 times higher than in the general population, with
cancer, lung, cardiac complications and infections being the most common
causes of deaths. Poor prognostic factors include older age, male gender, non-
Caucasian ethnicity, longer symptom duration, cardiac involvement, dysphagia,
malignancy and serum myositis-specific antibodies
3.10 ANTINUCLEAR ANTIBODIES
It is currently accepted that ANA contains two major types of antibodies.
The first group includes antibodies against DNA and histones which are
indicative of SLE and drug-induced lupus erythematosus (DILE), respectively.
The second group includes autoantibodies to extractable nuclear antigens
(ENA) which are obtained by extracting them from nuclei with saline. The
autoantibodies to Smith antigen (Sm) ribonucleoproteins (RNP), Ro/SSA or
La/SSB, Scl-70, histidyl-tRNAsynthetase (Jo-1), and PM1 are in this group, and
they have different sensitivity and specificity values depending upon the
underlying specific RD(40)
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3.10.1 types of ANA
ANA – the two broad subtypes Presently the ANA have been
categorized in to 2 main groups:
1.Autoantibodies to DNA and histones
These include antibodies against single and doublestranded DNA
(dsDNA) discovered way back in 1957. Significant levels of anti-dsDNA
antibodies are considered to be confirmatory in diagnosis of SLE. This was
followed by detection of anti-histone antibodies in 1971 which are indicative of
drug-induced SLE(41-45)
2. Autoantibodies to extractable nuclear antigens (ENA)
Besides DNA and histones, autoantibodies may also target other nuclear
antigens. These nuclear antigens were named ENA as originally they were
extracted from the nuclei with saline [8]. Autoantibody to Smith antigen (Sm)
which is considered to be specific for SLE was the first anti-ENA detected in
1966 [9]. Thereafter further subtypes of ENA i.e. ribonucleoproteins (RNP),
SSA/Ro, or SSB/La, Scl-70, Jo-1 and PM1 were more clearly identified(46,47)
Although most of these ENA are disease specific, still a significant
overlap exists. The sensitivity and specificity also varies depending upon the
type of underlying CTD(48,49).
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3.10.1 Anti-Sm antibodies
Anti-Sm and anti-RNP antibodies bind to related but distinct antigens.
The Smith antigens are a series of nuclear nonhistone proteins complexed with
small nuclear RNAs. The complexes are called small nuclear ribonucleoprotein
particles (snRNPs) and are important in the splicing of precursor messenger
RNA(50) Anti-Sm antibodies are mostly found only in SLE patients. Although
their sensitivity is not so high for SLE since they can only be detected in 25-
30% of the patients, their specificity is very high, making the test very useful for
confirming the diseases but not successful for ruling them out(51) They are
usually associated with high titers of ANA and can not be used for monitoring
the disease in the way that is possible for anti-dsDNA. Most laboratories use
either ELISA or hemagglutination to detect these antibodies(52)
3.10.2 Anti Ro/SSA - anti La/SSB antibodies
Anti Ro/SSA and anti La/SSB antibodies target cellular proteins
complexed with small nuclear RNAs. They are frequently seen in SLE and SS
patients and their presence is one of the criteria for the diagnosis and
classification of SS(53) They are rare in the general population and in diseases
other than SS and SLE, although they can be detected in scleroderma,
polymyositis, MCTD, and RA. Anti Ro/SSA and anti La/SSB antibodies can
also be found in patients who satisfy SLE criteria with negative ANA. Anti
Ro/SSA antibodies are found in 50% of patients with SLE and are associated
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with photosensitivity, cutaneous vasculitis, and interstitial lung disease(54) They
can be detected in 40-90% of primary SS patients but not as frequently in
patients with secondary SS (10-15%)(53) In addition, they are associated with
neonatal lupus and congenital heart block. Anti La/SSB antibodies generally
show parallelism to anti Ro/SSA antibodies. They are found in 10-15% of SLE
patients and 20-50% of primary SS patients. The mothers of babies born with
congenital heart block have an 80% probability of exhibiting anti Ro/SSA and
anti La/SSB antibodies, even in the absence of an RD.Only 1% of all
seropositive mothers will have babies with neonatal lupus syndrome or
congenital heart block.The antibodies should be measured under the following
conditions: 1) suspicion of SLE and primary SS (even if the ANA is negative),
2) mothers of babies with neonatal lupus and congenital heart block, and 3)
patients with SLE who are planning to get pregnant.
3.10.3 Anti-scl-70 antibodies
In 1979, a basic, heat-labile, chromatin-associated, nonhistone 70 kDa
protein against which autoantibodies from patients with SSc are detected was
described; it was isolated from rat liver nuclei with a combination of biologic
and immunologic methods. This was initially designated Scl-70. Subsequent
analyses revealed this response to be directed against topoisomerase I . Anti-
Scl-70 antibodies have classically been determined by double immunodiffusion
techniques against calf or rabbit thymus extract, including Ouchterlony and
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counterimmunoelectrophoresis (CIE). However, ascertainment of anti-Scl-70
antibodies by immunodiffusion (ID)   usually requires 2–3 days and is difficult
to automate. To circumvent this problem, IB and ELISA have been introduced
more recently
Autoantibodies to Scl-70 target against topo-I(55) .Anti-Scl-70 is detected
in about 20-40% of systemic sclerosis patients and may increase the risk for
pulmonary fibrosis, diffuse cutaneous involvement, and nephropathy. Although
the sensitivity is low, specificity approaches 100%. If the antibodies are
detected in patients with Raynaud’s syndrome, scleroderma is almost always
diagnosed since specificity is 98% and positive LR is 10. However, the test is
useless for ruling out the disease as the sensitivity is low (28%) and the negative
LR is 0.7.
Anti-Scl-70 antibodies carry an increased SSc-related mortality rate,
owing to the higher rate of right heart failure in association with RLD and
pulmonary fibrosis (56,57). Although no convincing association has been
established for anti-Scl-70 and scleroderma renal crisis in other studies, such an
association has been shown in one study of Japanese patients with SSc (58).
3.10.4 Anti-Jo-1 antibodies
Anti-Jo-1 antibody is a myositis specific autoantibody most commonly
found in patients with idiopathic inflammatory myopathies (IIM). This antibody
is directed against the histidyl-tRNA synthetase which catalyses the binding of
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the histidine to its cognate tRNA during protein synthesis. It can be considered a
specific marker of IIM, predominantly found in 20–30% of patients with PM
and in the 60–70% of those with interstitial pulmonary fibrosis. These
antibodies are also found in DM, although less frequently than in PM, and are
rare in children with PM or DM and in other connective tissue diseasesThe
detection of this antibody is particularly useful in diagnosis and classification of
IIM. Moreover, anti-Jo-1 serum levels strongly correlate with disease activity
representing a good marker for disease monitoring.
3.10.5 Anti-RNP antibodies
The anti-RNP system binds to antigens containing only U1-RNA that are
different from but related to Sm antigens. Anti-RNP antibodies are detected in
30-60% of SLE patients but are not specific for them.
They are also associated with Raynaud’s syndrome and a milder
probability of renal involvement(59). They are useful in diagnosing MCTD with
an unknown performance since the presence of the anti-U1 RNP antibody is one
of the criteria for MCTD(60,62) . The antibodies can be found in low titers in
scleroderma, and anti-U1 RNP may indicate pulmonary fibrosis and joint
involvement in this connective tissue disease(61,63)
35
Antibodies to extractable nuclear antigens in different connective tissue
diseases (CTDs)
Autoantibody Associated CTD
Anti-Sm High specificity of SLE, but low
sensitivity
Anti-Ro (SSA) Occurs in SLE, especially with
cutaneous involvement, and is
common in Sjögren’s syndrome.
Seen in mothers with neonatal SLE
Anti-La (SSB) Sjögren’s syndrome, SLE
Anti-RNP Non-specific, but is part of the criteria
for MCTD; also occurs in SLE
Anti-Jo-1 Highly specific for a severe form of
PM-DM, but not sensitive
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3.11 INDICATIONS FOR ENA TESTING
The common indications are to establish a diagnosis of CTDs in patients
with suggestive clinical features; to exclude CTDs in patients with few or
uncertain clinical findings; to subclassify patients known to have CTDs into
prognostic groups; and to monitor disease activity. Each of these indications,
however, demands a test with different performance characteristics to yield
meaningful information. ANA test is not sufficiently specific to establish a
diagnosis of a CTD, and a more specific confirmatory test, such as an anti-
doublestranded DNA (dsDNA) or an anti-ENA antibody test, is indicated.
The European Consensus Workshops recommended that ENA testing be
performed by two or more methods(64). This recommendation is difficult to
implement, particularly in the current era of cost containment. Rather, it may be
possible to achieve the same outcome by combining the sensitivity of the ANA
test with the specificity of a test for anti-ENA antibodies. We consider CIEP to
be the most appropriate method for detecting anti-ENA antibodies because of its
high specificity . In practice, most laboratories have chosen to use an ELISA-
based method for its simplicity, convenience, and rapid turnaround time.
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3.12 ENA DETECTION METHODS
3.12.1 EIA/ELISA
There are two types of EIA or ELISA methods currently used for ANA
testing. One is called generic assay which detects ANA of broad specificity
similar to IF-ANA and other is antigen specific assay that detects ANA and
reacts with a single autoantigen i.e. dsDNA, SS-A/Ro, SS-B/La, Scl-70, Sm,
Sm/RNP etc. In antigen specific assay multiple antigens are coated on to
microtitre plates, usually a combination of SSA/Ro, SSB/La, Sm, and   U1-
RNP, with many also including Jo-1 and Scl70. This new test is both highly
specific and sensitive and substantially decreases the time involved when
screening large numbers of patient samples. The test is simple to perform, can
be automated and does not require highly trained operators who can recognize
microscopic patterns.
The EIA/ELISA is therefore becoming the most widely used method not
only for routine screening but also for detection of specific ANA. Kits available
in the market either utilize extracts of tissue containing various nuclear
components or molecules synthesized by recombinant technology. The later
may include individual recombinant molecules such as SS-A/Ro, or
combinations of molecules which increase the sensitivity of the test. In a recent
study, the performance of ELISA test was compared with the "gold standard"
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IF-ANA test. The agreement that a serum is ANA positive was 87% to 95%
when comparing the ELISA and IF-ANA test results(65).
The sensitivity of the various ELISAs was 69% to 98% and the
specificity ranged between 81% and 98%. These figures were arrived at using
sera that were positive at 1:160 by the IF-ANA test. The above comparison
figures were much lower for sera with IF-ANA titer of 1:40. Although the
second multicentre European study showed that ELISA methods are improving
(66)
, the recent study by Bizzaro et al suggests that the problem of false positive
results in ELISA is still widespread(67). ELISA may miss anti-SSA/Ro even
when using the reference sera. This is probably a result of the vigorous antigen
preparation methods. Sera that react only with conformational antigens can also
miss the presence of antigen. The ELISA techniques have also been found to
miss a low titer positive ANA as well as sera with specific ANA. Presently,
ELISA tests therefore may be adequate to screen sera only with intermediate to
high titers. It remains to be seen from further studies whether the performance
of screening ANA tests by ELISA would match that by the fluorescent
technique(68)
3.12.2 CLIF
Aarden and his colleagues in 1975 used IF- ANA test for detection of
dsDNA antibodies by using a haemoflagellate C. luciliae as the substrate (69).
The organism is related to trypanosomes and is equipped with an intracellular
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organelle, the kinetoplast. The kinetoplast contains dsDNA in high
concentration while apparently not containing any other recognizable nuclear
antigens. The test is most useful in primary diagnosis of SLE with high
specificity when compared to ELISA(70). Although the sensitivity is comparable
to Farr assay, CLIF is easy to perform, possesses an intrinsic check on the
immunoglobulin character of the DNA-binding activity, determines the Ig
classes and subclasses of antibodies to DNA. In addition, there is an absence of
interference with antibodies to single-stranded DNA(71).
3.12.3 FARR ASSAY
The Farr assay is a radio-labeled assay which quantifies antibody to a
given antigen in sera through precipitation of antibody-antigen complexes on
addition of ammonium sulfate at high concentration. A radio-labeled antigen
(dsDNA) allows the quick determination of proportion of the antibody in the
precipitate. The Farr assay is quite specific and has been advocated as the most
reliable assay. However, it is time-consuming, technically difficult and involves
the use of radioactive material(72).
3.12.4 Gel precipitation assays
Techniques of precipitating antibodies to ENA were discovered and used
as diagnostic tools in CTD almost 5 decades ago(73). The early work relied
mainly on gel based techniques i.e. double immunodiffusion (DID) or counter
current immunoelectrophoresis (CIE)(74,75). CIE has been shown in several
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studies to be more sensitive than DID(76,). These gel precipitation assays
however have some limitations. They are not quantitative and disease sensitivity
is poor(77). Therefore several other approaches were explored, with the aim of
increasing assay sensitivity but without a loss of disease specificity
3.12.5 Passive haemagglutination (PHA)
The PHA method was quite popular in the late 1970s but has since been
superseded by EIA/ELISA and western blot. Analysis appears to have been
restricted to anti-Sm and anti-RNP antibodies. Although assay sensitivity is
high, some problems with specificity, in particular with differentiating
anti-Sm from anti-U1-RNP, have been described.
3.12.6 Western (immuno) blot
Immunoblotting was introduced in the 1980s and has been useful in
refining our understanding of the spectrum of ANA. In this method first the
nuclear and cytoplasmic antigens are separated according to their molecular
weight by polyacrylamide gel electrophoresis and then transferred onto a
membrane or strips. Antigen containing strips are incubated with control or
patient serum. If present in the serum, a particular ANA binds to the specific
antigen on the strip. After repeated washing and incubations with two types of
conjugates and a chromogen substrate, positive reactions are indicated by a
band on thestrip. The specificity of the antibody is defined by the identification
of the positive bands in comparison with the positive control strip.
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Although considered to be highly sensitive for anti-ENA a major
disadvantage with this technique is that antibodies directed against
conformational epitopes are not detected(78). In several studies, immunoblotting
was found to be particularly insensitive for anti-SSA/Ro(78,79). This apparent
paradox is explained by the fact that the higher resolution seen in western
blotting detects only linear epitopes whereas some 15% of anti-SSA/Ro
antibodies react only with conformational epitopes not detectable in western
blot. Moreover western blot is considered to be inadequate for anti-Scl70 with
an assay sensitivity of only 25% (80). Also sometimes there may be a problem
with the under detection of U1-RNP(81,82). Again, disease specificity is poor and
in studies on normal populations false positives are not infrequent.
3.12.7 Dot blot
The dot blot method is a qualitative assay, which utilizes strips of
nitrocellulose on which purified antigens are blotted at pre-located spots. The
antigen sources used are bovine and rabbit thymus (for SSA, Sm and Scl-70) or
calf spleen and rabbit thymus (for SSB and Sm/RNP). The strips are incubated
with a 50-fold dilution of patient serum followed by incubation with an alkaline
phosphatase- protein A conjugate. Finally the test strips are  stained with 5-
bromo-4-chloro-3-indolylphosphate/ nitroblue tetrazolium. Positive strips are
stained as a blue spot(83). The dot blot test is advantageous for time management
as the test requires just 30 minutes, can be easily performed and relatively
cheaper. A major drawback however is the blotting of RNP antigen in
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combination with Sm antigen. This implies that if both the Sm spot and the
Sm/RNP spot are positive the presence of Sm antibodies alone cannot be
distinguished from the combined presence of Sm and RNP antibodies.
3.12.8 Line blot Immunoassay
Line blot Immunoassay is another qualitative test which reveals antibody
reactivity to antigens that are applied as distinct lines on a membrane. Specific
nuclear antigens are applied to nitrocellulose strips at equal distances. The
required number of strips is placed to the respective row of the incubation tray.
To rehydrate and to block free binding sites against unspecific binding, the
strips are  incubated with buffer, containing blocking protein. After discarding
the blocking buffer, the membrane strips aremincubated with prediluted serum
samples. According to their specificity, autoantibodies, if present in the sample
bind to the antigens are traced by alkaline phosphatase conjugated anti-human-
IgG antibodies and appear as blue stained bands on the strips. Like dot blot, line
blot is also easy to use and requires less processing time and is comparable to
ELISA in sensitivity and specificity. Automated interpretation is also
possible(84).
3.12.9 Multiplex Immunoassay (MIA)
The newly developed MIA enables the detection of multiple specific
ANA as separate entities at the same time (85,87). In MIA the patient sera is
incubated in a well containing a multiplexed mixture of the bead suspension.
The bead suspension consists of polystyrene microspheres that are conjugated
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with different antigens and nuclear extract of Hep-2 cells. If the patient serum
contains antibodies to any of the antigens or Hep-2 nuclear extract, the antibody
will bind to the immobilized antigen on 1 or more of the bead sets. The
antibody-antigen-bead complex is then incubated with phycoerythrin
conjugated goat anti-human IgG and the bead suspension is then analysed by
the immunoassay analyzer. The beads are uniquely identified by their
corresponding fluorescent dye, and the amount of phycoerythrin conjugate is
determined for each antigen. Multiplex ANA testing is being claimed to be
more efficient and technically less challenging than IFANA screening,
decreases false positivity, removes subjectivity and is more efficient than
conventional ELISA(86).
3.12.10 Flowcytometry
Flowcytometry with autoantigen-coated fluorescent beads has been
gaining popularity in recent years. It gives quantitative results based on
reactivity with a mixture of bead subsets that are each labeled with a unique
combination of internal fluorescent signal and antigen. Fluorescent beads-based
techniques, also commonly referred to as Reflex ANA, are claimed to have
multiple advantages such as simultaneous testing for recognition of several
antigens, automation, cost effectiveness and high sensitivity. However, most
significant limitation of this method is that it provides only a single result for
each analysis. Often, multiple tests are necessary in order to be able to report a
complete repertoire of required autoantibody results(88,89).
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3.12.11 Antigen microarray
Antigen microarray currently not widely performed but may be an
excellent advancement for simultaneous measurement of multiple ANA. This is
a nanotechnology technique in which pre-synthesized antigens are printed on
polystyrene and incubated with serum samples and then with horseradish
peroxidase-conjugated secondary antibodies and chemiluminescent substrates.
Light signals produced are captured by a charge-coupled device camera based
chip reader. Antibodies are quantified by use of calibration curves (90). The
method offers the advantages of complete automation, consistent performance,
cost-effectiveness and more precise measurement of antibody levels. The results
are largely comparable to those obtained with techniques currently used in
clinical laboratories (91,92). Microarray may also be suitable for the discovery and
evaluation of novel autoantibodies(93).
Among the above mentioned techniques choice depends on multiple
factors i.e. test required for screening or detection of specific ANA, sensitivity
and specificity of the test, availability, cost effectiveness, time taken and skill
required to perform the test
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4. MATERIALS AND METHODOLOGY
Materials:
4.1.1 Study Population and Study Period
This study was done over a period of 12 months from April  2016, after
obtaining clearance from our  institutional ethical committee .
4.1.2 Study group
It included patients with signs and symptoms suggestive of CTD  who
have attended Rheumatology  department, Tirunelveli Medical College Hospital
(TVMCH). A total of 50 clinically suspected CTD with  complaints related to
connective tissue disorders like skin rashes ,photosensitivity, joint pain,
respiratory symptoms and were ANA positive, in the age group of 15-65 years
of  both sexes were included.
4.1.3 Control group
A total of 50 controls with out any clinical symptoms related to
connective tissue disorders and with ANA negative , in the age group of 15- 65
years of both sexes
4.1.4 INCLUSION CRITERIA:
 Patients suspected to have clinical signs and symptoms related to
connective tissue disorders
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 Age group 15 – 65 years
4.1.5 EXCLUSION CRITERIA:
 Patients with Rheumatoid arthritis or Osteoarthritis
 Patients with non-specific symptoms like fatigue, back pain or
other musculoskeletal pain, without suggestive skin lesions.
 Age group up to 15 years
4.1.6 Ethical clearance
Ethical clearance was obtained from the college ethical committee before
the commencement of the study.
4.1.7 Consent
Informed written consent was obtained from all patients involved in the
study, both study and control group.
4.1.8 Proforma:
The proforma was filled with the details like name , age , sex , clinical
symptoms like  skin rashes ,photosensitivity, joint stiffness and bone
involvement , breathlessness ,seizures, clinical diagnosis and other parameters
relevant to the present study.
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4.1.9 Sample collection
After  getting informed  consent , blood was collected from median
cubital vein , selected area was cleaned with surgical sprit and allowed to air
dry , 5 ml blood was collected .Collected whole blood specimens using
acceptable medical techniques to avoid haemolysis.
4.1.10 Separation of serum from sample
Blood was collected in sterile glass tubes, and sample container was kept
in slanting position at room temperature for 30 minutes. From the specimen
vial, serum was transferred to sterile screw capped leak proof tube. It was
confirmed that test serum was clear and non-hemolyzed. Contamination by
hemolysis or lipemia was avoided, Lipemic, lysed, deteriorated samples were
discarded.
4.1.11 Storage of serum
Serum vials were packed in a second tightly capped unbreakable
container, surrounded by adequate packing material and stored at -20°C deep
freezer.
4.1.12 Biomedical waste management
As the materials handled were highly infectious, proper biomedical waste
management was followed throughout the study.
49
Methods:
Blood samples were taken from 50 clinically suspected CTD patients and
50 controls and tested for ENA screening by ELISA and positive samples were
tested for specific antibodies like SS-A, SS-B, Sm , RNP/ Sm , Scl-70 , Jo-1 by
ELISA
4.2 ENA SCREENING DONE BY ELISA
4.2.1 PRINCIPLE OF THE PROCEDURE
Diluted samples were incubated with ENA antigens (SSA, SSB, m/RNP,
Scl- 70 and Jo-1) bound to the solid surface of a microtiter well. If IgG
antibodies against any of these antigens were present in the samples they will
bind to the respective antigen forming antigen-antibody complexes. Residual
sample was eliminated by aspirating and washing. Conjugate (alkaline
phosphatase labeled anti-human IgG) was added and will bind to these
complexes. Unbound conjugate was removed by aspiration and washing.
Substrate was then added and incubated. In the presence of bound enzyme the
substrate was converted to a coloured end product. The absorbance of this end
product can be read spectrophotometrically at 405 nm (reference 600-630 nm).
4.2.2 REAGENTS
Each -ENA-6 Screen Test Kit contains reagents for 96 tests.
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Antigen Wells :Twelve, 8-well microwell breakapart strips, color-coded gold,
coated with purified extractable nuclear antigens (SSA, SSB, Sm/RNP, Scl-70
and Jo-1).
Cut-Off Calibrator: One vial with blue cap containing 0.25 ml human serum,
weakly reactive for ENA IgG antibodies, 0.1% sodium azide.
Low Positive Control: One vial with white cap containing 0.25 ml human
serum reactive for ENA IgG antibodies, 0.1% sodium azide.
Negative Control: One vial with black cap containing human serum,
nonreactive for ENA IgG antibodies, 0.1% sodium azide.
Sample Diluent: One bottle with blue cap containing 60 ml Phosphate buffer
with protein stabilizers. Contains 0.1% sodium azide and Proclin® 300, 90 ppm
active ingredient. Color-coded blue.
Wash Concentrate (20X): Two bottles with clear caps containing 50 ml of
Phosphate buffered saline with detergent and Proclin® 300, 15 ppm active
ingredient. Each bottle is sufficient to make 1050 ml of wash solution.
Conjugate : One bottle with red cap containing 25 ml goat antihuman
immunoglobulin G labeled with alkaline phosphatase. Also includes protein
stabilizers and Proclin® 300, 30 ppm active ingredient. Color-coded pink.
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Substrate: One amber bottle with brown cap containing 25 ml buffered p-
Nitrophenyl phosphate solution. Substrate solution may develop a slight yellow
color upon storage.
Stop Solution: One bottle with white cap containing 30 ml of Sodium
phosphate, tribasic. Solution is caustic. Avoid contact with skin or eyes. If
contact is made, flush area with copious amounts of water.
Store these reagents at 2 to 8° C
4.2.3 MATERIALS REQUIRED
• Microplate reader capable of endpoint measurements at 450 nm; optional:
reference filter at 620 nm
• Data reduction software
• Multi-channel dispenser or repeatable pipette for 100 μl
• Vortex mixer
• Pipettes for 10 μl, 100 μl and 1000 μl
• Laboratory timing device
• Distilled or deionised water
• Measuring cylinder for 1000 ml and 100 ml
• Plastic container for storage of the wash solution
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This ELISA assay is suitable for use on open automated ELISA
processors. Each assay has to be validated on the respective automated system
4.2.4 PROCEDURE
1. A 1:101 dilution of samples in Sample Diluent was made and mixed well.
2. 100 μl of diluted samples into the antigen wells were added. Reserved one
well for reagent blank (100 μl of Sample Diluent).
3. Incubated at room temperature (18 - 30° C) for 30 ± 5 min.
4. The contents of the wells were discarded. Washed the wells 3 times with
Wash Solution.
5. 100 μl of Conjugate was added to each well.
6. Incubated at room temperature (18 - 30° C) for 30 ± 5 min.
7. Washed the wells as in #4 above.
8. 100 μl Substrate Solution was added to each well.
9. Incubated at room temperature (18 - 30° C) for 30 ± 5 min.
10. 100 μl Stop Solution was added to each well.
11. Read the absorbance at 405 nm (reference at 600 - 630 nm) against the
reagent blank.
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4.2.5 CALCULATION
Calculate the mean absorbance of the Cut-Off Calibrator. When
calculating the mean absorbance value for the Cut-Off Calibrator exclude any
absorbance value that deviates by more than 15% from the MEAN absorbance
value. Calculate the mean from the two remaining absorbance values.
Absorbance of Sample
Mean Absorbance of  ̿ Index Value of Sample
Cut-Off Calibrator
4.2.6 INTERPRETATION OF RESULTS
Index Value Interpretation
< 0.9 Negative for anti-ENA IgG antibodies
0.91 to 1.09 Equivocal
≥ 1.10 Positive for anti-ENA IgG antibodies
4.3 ENA Profile done by ELISA
4.3.1 PRINCIPLE OF THE TEST
Highly purified antigens SS-A (52 and 60 kDa), SS-B, Sm, RNP/Sm,
Scl-70 and Jo-1 were bound to microwells. Antibodies against the coated
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antigen, if present in diluted patient sample, bind to the respective antigen.
Washing of the microwells removes unbound unspecific serum and plasma
components.
Horseradish peroxidase (HRP) conjugated anti-human antibodies
immunologically detect the bound patient antibodies forming a
conjugate/antibody/antigen complex. Washing of the microwells removes
unbound conjugate. An enzyme substrate in the presence of bound conjugate
hydrolyzes to form a blue colour. The addition of an acid stops the reaction
forming a yellow end-product. The intensity of this yellow colour is measured
photometrically at 450 nm. The amount of colour is directly proportional to the
concentration of antibodies present in the original sample.
4.3.2 CONTENTS OF THE KIT
Sufficient for 96 determinations
1 One divisible microplate consisting of 12 modules of 8 wells each. Ready to
use.
1x 1 ml Calibrator SS-A (cut-off), containing SS-A antibodies in a
serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to
use.
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1x 1 ml Calibrator SS-B (cut-off), containing SS-B antibodies in a
serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to
use.
1x 1 ml Calibrator Sm (cut-off), containing Sm antibodies in a serum/buffer
matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
1x 1 ml Calibrator RNP/Sm (cut-off), containing RNP/Sm antibodies in a
serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to
use.
1x 1 ml Calibrator Scl-70 (cut-off), containing Scl-70 antibodies in a
serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to
use.
1x 1 ml Calibrator Jo-1 (cut-off), containing Jo-1 antibodies in a serum/buffer
matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
2x 2 ml Control positive (1) and negative (2), containing ENA antibodies in a
serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to
use.
20 ml Sample Buffer P, containing PBS, BSA, detergent, preservative NaN3
0.09%, yellow, 5x conc.
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15 ml Enzyme Conjugate containing anti-human IgG antibodies, HRP
labelled; PBS, BSA, detergent, preservative ProClin 300 0.05%, light red.
Ready to use.
15 ml TMB Substrate; containing 3,3’, 5,5’- Tetramethylbenzidin, colorless.
Ready to use.
15 ml Stop solution; contains acid. Ready to use.
20 ml Wash Solution, containing Tris, detergent, preservative NaN3 0.09%; 50
x conc.
4.3.3 MATERIALS REQUIRED
• Microplate reader capable of endpoint measurements at 450 nm; optional:
reference filter at 620 nm
• Data reduction software
• Multi-channel dispenser or repeatable pipette for 100 μl
• Vortex mixer
• Pipettes for 10 μl, 100 μl and 1000 μl
• Laboratory timing device
• Distilled or deionised water
• Measuring cylinder for 1000 ml and 100 ml
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• Plastic container for storage of the wash solution
This ELISA assay is suitable for use on open automated ELISA processors.
Each assay has to be validated on the respective automated system
4.3.4 STORAGE AND STABILITY
• Store test kit at 2-8°C in the dark.
• Do not expose reagents to heat, sun, or strong light during storage and usage.
• Store microplate sealed and desiccated in the clip bag provided.
• Unopened reagents were stable until expiration of the kit. See labels for
individual batch.
• Diluted Wash Solution and Sample Buffer were stable for at least 30 days
when stored at 2-8°C.
4.3.4 PREPARATION OF REAGENTS
Wash Solution
Dilute the contents of one vial of the buffered wash solution concentrate
(50x) with distilled or deionised water to a final volume of 1000 ml prior to use.
Sample Buffer P
Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x
concentrate with distilled or deionised water to a final volume of 100 ml.
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Preparation of samples
Dilute patient samples 1:100 before the assay: Put 990 μl of prediluted
sample buffer in a polystyrene tube and add 10 μl of sample. Mix well. Note:
Calibrators / Controls are ready to use and need not be diluted.
4.3.5 TEST PROCEDURE
Prepared enough microplate modules for all calibrators / controls and
patient samples.
1. Pipetted 100 μl of calibrators, controls and prediluted patient samples into the
wells.
2. Incubated for 30 minutes at room temperature (20-28 °C).
3. Discarded the contents of the microwells and washed 3 times with 300 μl of
wash solution.
4. Dispensed 100 μl of enzyme conjugate into each well.
5. Incubated for 15 minutes at room temperature.
6. Discarded the contents of the microwells and washed 3 times with 300 μl of
wash solution.
7. Dispensed 100 μl of TMB substrate solution into each well.
8. Incubated for 15 minutes at room temperature
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9. Added 100 μl of stop solution to each well of the modules
10. Incubated for 5 minutes at room temperature.
11. Read the optical density at 450 nm (reference 600-690nm) and calculate the
results. The developed colour is stable for at least 30 minutes. Read during this
time.
4.3.6CALCULATION OF RESULTS
For qualitative results: for each antigen of the profile the optical density
(OD) of a sample is compared to the OD of the antigen-specific Calibrator
Negative: OD sample < OD Calibrator
Positive: OD sample ≥ OD Calibrator
For detailed results the optical density of a sample is expressed as Index value:
Index = OD sample / OD Calibrator
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Interpretation of results
Negative: Index < 1.0
Borderline: Index 1.0 - 1.2
Positive: Index > 1.2
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5. RESULTS
Study group
A total of 100  patients were included in the study.50 ANA positive
subjects with signs and symptoms related to connective tissue disorders( CTD)
were evaluated against  50 ANA negative controls with out any signs and
symptoms related to CTD. This study was conducted for a study period of one
year from April  2016 to March 2017. The study population mainly consisted
of patients  attending  Rheumatology Department, Tirunelveli Medical College
Hospital, Tirunelveli.
Statistical analysis and interpretations:
The ANA positive and negative study subjects were described and
interpreted according to the type of variables. The continuous variables were
described in terms mean and interpreted by student independent “t” tests. The
categorical variables were analyzed in terms of percentages and interpreted by
χ2 (Chi-square) tests. The Chi-squared test was calculated for the analytic
assessment by SPSS 20 version software The screening tests were applied to
predict sensitivity and specificity. The P- values less than or equal to 0.05
(P≤0.05) were treated as statistical significant.
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Table-1: Age wise distribution of ANA positive subjects and ANA negative
controls
Age group
(years)
ANA Positive ANA Negative
Frequency % Frequency %
<20 5 10.0 2 4.0
20-29 9 18.0 17 34.0
30-39 20 40.0 11 22.0
40-49 8 16.0 13 26.0
50-59 6 12.0 6 12.0
60+ 2 4.0 1 2.0
Total 50 100.0 50 100.0
Mean ± SD 36.1±13.0 36.8±11.0
Significance t=0.281, df=98, P>0.05
The ANA positive and negative subjects have been classified and compared
according to their age in the above table-1. The positive subjects were 40% in
the ages of 30-39 and negative subjects were 34% in the ages of 20-29 . The
mean age of positive subjects was 36.1± 13.0 years and the mean age of
negative subjects was 36.8± 11.0 years. The difference of ages between the two
groups was not statistically significant (P>0.05).
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Figure 1:   Age wise distribution of ANA positive subjects and ANA
negative controls
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Table-2: Gender wise distribution of ANA positive subjects and ANA negative
controls
Gender
ANA positive ANA Negative Total
χ2 df Sig
No % No % No %
Male 4 8.0 15 30.0 19 19.0
6.498 1 P<0.05Female 46 92.0 35 78.0 81 81.0
Total 50 100.0 50 100.0 100 100.0
The table-2 states the gender wise classification and its relation with the
gender. The difference between males (30%) and females (92%) was
statistically significant (P<0.05).
Figure -2
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Table-3 Clinical symptoms among ANA positive subjects
Associated symptoms Present Percentage
Skin rash 28 56%
Bones 35 70%
CVS 1 2%
RS 9 18%
Renal 5 10%
Photosensitivity 4 8%
CNS 3 6%
Hypothyroidism 4 8%
The most common symptoms were skin rash (56%), bone involvement (70%),
Figure -3
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Table-4: Anti ENA positivity among ANA positive subjects and ANA
negative controls :
ENA ANA
Positive Negative Total
Positive 28 3 31
Negative 22 47 69
Total 50 50 100
The sensitivity of the ENA screening test was 56%, The specificity of the
test was 94%, The positive predictive value of the test was 90.3%, The negative
predictive value of the test was 68.1%,
Figure -4
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Table-5: Distribution of antibody to SSA among ANA positive subjects
Antibody to SSA ANA
Positive Negative Total
Positive 17 0 17
Negative 33 50 83
Total 50 50 100
The sensitivity of the test was 34%, The specificity of the test was
100%, The positive predictive value of the test was 100%, The  negative
predictive value of the test was 60.2%,
Figure -5
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Table-6:Distribution of antibody to SSB among ANA positive subjects :
Antibody to SSB ANA
Positive Negative Total
Positive
6 0 6
Negative 44 50 94
Total 50 50 100
The sensitivity of the test was 12%, The specificity of the test was 100%,
The positive predictive value of the test was 100%, The negative predictive
value of the test was 53.2%,
Figure-6
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Table-7: Distribution of antibody to Sm among ANA positive subjects :
Antibody to Sm ANA
Positive Negative Total
Positive
16 2 18
Negative 34 48 82
Total 50 50 100
The sensitivity of the test was 32%, The specificity of the test
was 96%, The positive predictive value of the test was 88.9%, The
negative predictive value of the test was 58.5%,
Figure-7
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Table-8:Distribution of antibody to RNP/ sm among ANA positive subjects:
Antibody to RNP/ sm ANA
Positive Negative Total
Positive
18 3 21
Negative 32 47 79
Total 50 50 100
The sensitivity of the test was 36%, The specificity of the test
was 94%, The positive predictive value  of the test was 85.7%, , The
negative predictive value  of the test was 59.5%,
Figure -8
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Table-9: Distribution of antibody to SCL 70 among ANA positive
subjects
Antibody to SCL 70 ANA
Positive Negative Total
Positive
4 0 4
Negative 46 50 96
Total 50 50 100
The sensitivity of the test was 8%, The specificity of the test was 100%,
The positive predictive value of the test was 100%, The negative predictive
value  of the test was 52.1%,
Figure -9
4%
96%
Distribution of antibody to SCL 70 among ANA
positive subjects
Positive Negative
72
Table-10:Distribution of antibody to JO-1among ANA positive subjects
Antibody to JO1 ANA
Positive Negative Total
Positive
0 0 0
Negative 50 50 100
Total 50 50 100
None of the ANA positive subjects exhibited JO1 antibody.
Figure-10
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Table-11: Clinical diagnosis of  ENA positive subjects
Sl No Clinical diagnosis Frequency %
1 MCTD 5 10.0
2 SLE 20 40.0
3 Systemic sclerosis 3 6.0
4 Sjogrens syndrome 3 6.0
4 Others 19 38.0
Total 50 100.0
20 patients had a clinical diagnosis of SLE,5 had MCTD,3 patients had
systemic sclerosis and another 3 had Sjogrens syndrome. 19 had other CTDs.
Figure-11
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Table-12: Distribution of anti ENA subtypes among the clinical diagnosis :
Sl No Clinical diagnosis SSA SSB Sm RNP/Sm Scl-70
1 MCTD - - 3 5 -
2 SLE 15 6 12 11 1
3 Systemic sclerosis 1 - - 1 2
4 Sjogrens syndrome 1 - 1 1 1
4 Others - - - - -
Total
Among 20 SLE patients, 15 had  SSA,    6 had SSB, 12 had  Sm ,11 had
RNP/Sm ,and 1 patient had Scl-70.
Among 5 MCTD patients , 3 were positive with Sm and  5 were
RNP/Sm positive.
Among 3 Systemic sclerosis patients ,1 was positive with SSA , 1 was
positive RNP/Sm, and 2 were positive with Scl-70.
Among 3 patients  with Sjogrens syndrome, 1 was positive with SSA ,1
was positive with Sm and 1 was positive RNP/Sm and 1 with Scl-70
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Table -13 Age wise distribution of anti ENA positive subjects
Age ENA Positive (no=31) Percentage
<20 2 6.5 %
20-29 5 16.1%
30-39 12 38.7%
40-49 7 22.6%
50-59 4 12.9%
60+ 1 3.2%
ENA  positivity more in the age group between   30-39 years (12)
Figure -13
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Table -14 Gender Wise Distribution of  antiENA Positive subjects
Gender ENA Positive (no=31) Percentage
Female 28 90.3%
Male 3 9.7%
The above table -14 showed that females (28) are more prone for ENAs than
males(3)
Figure -14
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Table -15 Presence of  Skin rash among different anti ENA sub types
ENA Skin rash positivity Percentage
SSA (n-17) 13 32.5%
SSB n(6) 6 15%
Sm (16) 7 17.5%
RNP / Sm (n-18) 12 30%
SCL-70 (n-4) 2 5%
JO-1(n-0) 0 0%
The above table -16 stated that skin rash is more prevalent in SSA (13),and
RNP/sSm (12) positive patients
Figure -15
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Table -16 Presence of Bone involvement among different anti ENA sub
types
ENA Bone involvement
positivity
Percentage
SSA (n-17) 12 30%
SSB (n-6) 5 13.5%
Sm (n-16) 6 15%
RNP / Sm (n-18) 13 31.5%
SCL-70 (n-4) 2 5%
JO-1 (n-0) 0 0%
The above table -17 stated that bone involvement commonly associated with
SSA positive -12, and RNP/Sm positive subjects -13
Figure -16
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Table -17 Presence of Lung involvement among  different anti ENA sub
type
ENA Lung involvement Percentage
SSA (n-17) 4 32.5%
SSB (n-6) 1 15%
Sm (n-16) 1 17.5%
RNP / Sm (n-18) 3 30%
SCL-70 (n-4) 1 5%
JO-1(n-0) 0 0%
The above table -18 stated that  lung involvement is more common in patients
positive with SSA (4) and  RNP/Sm(3) antibodies
Figure -17
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Table -18 Association of Hypothyroidism among different  anti ENA sub
types
ENA Hypothyroidism Percentage
SSA (n-17) 1 20%
SSB (n-6) 1 20%
Sm (n-16) 0 0%
RNP / Sm (n-18) 2 40%
SCL-70 (n-4) 1 20%
JO-1(n-0) 0 0%
The above table -19 shows that hypothyroidism commonly associated with
RNP/Sm antibodies
Figure -18
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Table -19 Kidney involvement among anti ENA sub types
ENA Kidney involvement Percentage
SSA (n-17) 2 25%
SSB (n-6) 0 0%
Sm (n-16) 1 12. 5%
RNP / Sm (n-18) 3 37.5%
SCL-70(n-4) 2 25%
JO-1(n-0) 0 0%
The above table -20 showed that kidney involvement is not significantly
associated with ENA antibodies
Figure -19
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6. DISCUSSION
This study  was conducted on  100 subjects   which included  50 ANA
positive cases and 50  ANA negative controls .
Age and sex incidence
Among the cases , 40% were in the age group of 30-39 and  34% were  in
the age group of 20-29 among the controls. The mean age of cases was 36.1±
13.0 years and the mean age of controls  was 36.8± 11.0 years.
In this study ,92%females were ANA positive compared to males 8%.
In a  study conducted by Budhrani D et al:  incidence of CTD in Males
(20%) and females (80%) were seen making incidence ratio of 1:4 respectively.
Autoimmune connective tissue disease is commonly seen in middle age with
average age of occurrence ranging from 20-50 years. This result is in
accordance with reports from various authors viz. Malaviya et al [M: F= 1:8]
and Lee et al [M: F= 1:6](94,95). The median age of onset in present study was
around 40 years while study by Malaviya et al had 24years  and Masi et al had
31 years(96) as a median age
The  most common age group among ENA positive subjects was 30-39
years   and females (28) 90.3% were most commonly affected  compared to
males (3) 9.7%
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In the studies done by.Gunnarsson et al., 2011; Mahler & Fritzler, 2010
the prevalence of mixed connective tissue disease was around 0,003-0,004% in
adult individuals and was ten times more common in females.
In a study conducted by Fox RI. Sjogren’s syndrome ( Lancet 2005; 366:
321–31.) can occur in any age group, but it affects females than males as in
other CTDs (90% of all the patients). Sjogrens Syndrome occurs in the fourth,
fifth and sixth decades of life. Primary SS is found in approximately 0.1-0.2%
of individuals,  primary SS and secondary SS together are found in
approximately 1-3% of individuals and are nine times more common in females
In our study  66% of ANA positive patients were house wives and 34 %
were workers ( coolie).
Symptomatology
According to our study, subjects were most commonly affected with skin
rash (50%) and bone involvement (70%) . Lung (18%) and kidneys (10%) were
less commonly affected. A study conducted by Kun-yi wang the most common
initial presentations were joint pain(37.2%), followed by skin
presentations(14.4%) and sicca syndrome (12.4%)
ENA screening test
In our study 28  ANA positive subjects and 3   ANA negative subjects
were positive for ENA . Performance characteristics of the ENA screening test
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was analysed. Sensitivity of the test was 56% ,Specificity of the test was 94%
,Positive predictive value  90.3%,and Negative predictive value  68.1%
Among the 50 controls 3 were ENA positive. (6%).Although lower
amounts of autoantibodies can be found in the serum of apparently normal
individuals as well, particularly in older age groups, a spurt in titres is seen in
patients of autoimmune diseases.97,98 The frequency of autoantibodies in normal
individuals ranges between 0.5 and 27%.(98)
The prevalence of anti-ENA positivity combined with a negative
ANA was three out of 468 (0.64%) as found by Manoussakis et al (99)
ENA subtypes
In our study out of 100 subjects 31 were positive for ENAs. Among the  31
ENA  positive subjects SSA  was identified in 17 (54%) ,SSB in  6 (19%), Sm
in 16 ( 51%) , RNP/Sm  in 18 ( 58%) , Scl-70 in  4 ( 12 %)  patients
respectively.
Anti Ro/SSA antibodies are found in 50% of patients with SLE and are
associated with photosensitivity, cutaneous vasculitis, and interstitial lung
disease(54). They can be detected in 40-90% of primary SS patients
but not as frequently in patients with secondary SS (10-15%)(53).
Antibodies to SSA/Ro and SSB/La are specific for SS but are also found
in SLE and RA (Blomberg et al., 2000; Pisetsky, 2012; Schulter-Pelkum et al.,
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2009). Anti-SSA/Ro antibodies are found in approximately 30-60% of patients
with pSS, approximately 30- 40% of patient with SLE and approximately 3-
15% of patients with RA. Anti-SSB/La antibodies are found in approximately 5-
50% of patients with pSS and 15-20% of patients with SLE (Cavazzana et al.,
2006; Goëb et al., 2007; Rahman & Isenberg, 2008).
In the observation by  Sanchez-guerrero et al  anti-Sm was found in 23%,
anti-RNP in 27%, anti-SSA in 40%, and anti-SSB in 23% of study subjects .
The presence of anti-SSA/Ro antibodies can cause fetal heart block in 1-2% of
pregnant SLE patients (Damoiseaux & Cohen Tervaert, 2006; Rahman &
Isenberg, 2008).
Anti-Sm antibodies are mostly found only in  SLE patients. Although
their sensitivity is not so high for SLE since they can only be detected in 25-
30% of the patients, their specificity is very high, making the test very useful for
confirming the diseases (48). Anti-Sm antibodies are specific to patients with
SLE and are found in approximately 10-30 % of patients (Rahman & Isenberg,
2008; Tan & Kunkel, 1966).
Anti-Sm antibodies are stable throughout  the disease and are therefore
not linked to clinical manifestation (Pisetsky, 2012). Anti-Sm antibodies are
almost never found in individuals without autoimmune disease (Kurien &
Scofield, 2006). In this study also Anti Sm antibody was not detected among
ANA negative controls . Anti-Sm antibodies are detectable in a percentage of
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SLE patients comprised between 5 and 30%; they are more prevalent in blacks
and because of their high specificity for SLE have been included in the
serological criteria for diagnosing the disease
Anti-RNP antibodies are detected in 30-60% of SLE patients but are not
specific for them. They are also associated with Raynaud’s syndrome and a
milder probability of renal involvement.(60) They are useful in diagnosing
MCTD with an unknown performance since the presence of the anti-U1 RNP
antibody is one of the criteria for MCTD(48)
Habets et al., 1983; Ippolito et al., 2011; Tan, 1980; and von Mühlen &
Tan, 1995 have also found that Anti-RNP antibodies are associated with SLE
and MCTD but can also be found in patients with some other systemic
rheumatic diseases (Benito-Garcia et al., 2004). They are found in 75-90% of
patients with MCTD and in 30-40% of patients with SLE and are thought to be
found in patients with less severe disease (Tani et al., 2014; von Mühlen & Tan,
1995) .
In patients with anti-RNP antibodies, 40% have a well defined connective
tissue disease (SLE, PSS, polymyositis, or RA), 26 % have overlap syndromes.
Anti-RNP are detectable in 25-47% of SLE patients; high titers of anti-
RNP antibodies are diagnostic of mixed connective tissue disorder (MCTD).
The measurement of anti-Sm and anti-RNP antibodies is more important in the
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diagnosis of SLE than in the follow-up of patients. However, anti-RNP
antibodies are more prevalent in patients with Raynaud's phenomenon and are
associated with milder renal involvement.
Anti-Scl-70 is detected in about 20-40% of systemic sclerosis patients
and may increase the risk for pulmonary fibrosis, diffuse cutaneous
involvement, and nephropathy. Although the sensitivity is low, specificity
approaches 100%(55).
Anti-Scl-70 antibodies are antibodies that bind to DNA-topoisomerase I
(Ho & Reveille, 2003; von Mühlen & Tan, 1995). They are specific for
Systemic  sclerosis but the presence of anti-Scl-70 predicts a more severe course
of the disease (Damoiseaux & Cohen Tervaert, 2006; von Mühlen & Tan,
1995). Anti-Scl-70 antibodies are found in 10-40% of patients with SSc (Mahler
et al., 2010).
Anti JO-1 antibodies are most commonly found in patients with
Dermatomyositis and Polymyositis . However in our study none of the patient
had anti JO-1 antibody.
Clinical relation to ENA subtypes
In our study 20 patients had a clinical diagnosis of SLE,5 had MCTD,3
patients had systemic sclerosis and another 3 had Sjogrens syndrome. 19 had
other CTDs
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Among the 20  SLE patients, 15 had  SSA,    6 had SSB, 12 had  Sm ,11
had RNP/Sm ,and 1 patient had  Scl-70.  Among the 5 MCTD patients , 3 were
positive with Sm,and  5 were RNP/Sm positive.
Among the 3 Systemic sclerosis patients ,1 was positive with SSA , 1 was
positive RNP/Sm, and 2 were positive with Scl-70. Among  the 3 patients  with
Sjogrens syndrome, 1 was positive with SSA ,1 was positive with Sm and 1 was
positive RNP/Sm and 1 with Scl-70
The clinical symptoms of the  31 positive ENA subjects was analysed
which showed the following results .
 Skin rash was present in 13 SSA positive subjets and 12 RNP/Sm
positive subjects
 Bone involvement was noted in 11 SSA positive subjects and 12 RNP/Sm
positive subjects
 Lungs involvement was seen  in 4 SSA positive and 3 RNP.Sm positive
subjects
 Kidney involvement present in 2 SSA positive subjects , 3 RNP/Sm
positive subjects  and 2 Scl-70 posotive subjects
 Bone involvement was present in 12 SSA positive subjects and 13
RNP/Sm positive subjects
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Among SLE patients    Anti-Ro/SS-A antibodies showed the highest
sensitivity(61%), but also the lowest specificity (80%). Anti-Sm antibodies had
high specificity (88%), but low sensitivity (34%).
Anti-Ro antibodies do occur in patients with Systemic Sclerosis, but at a
lower frequency than in those with SLE or Sjögren syndrome (less than 35%) .
However, Sjögren syndrome has been described in up to 20% of all patients
with SSc, with about one-third to one-half of those with anti-Ro antibodies.
Sjögren syndrome is actually associated with about 35% of SSc patients
positive for anti-Ro.
Anti-Ro (SSA) antibodies, often accompanied by anti-La (SSB), are
found in 20 and 30% of SLE patients. The former have been found to be
associated with a higher prevalence of subacute cutaneous lesions and sicca
syndrome, but with a lower prevalence of thrombocytopenia. Anti-La (SSB)
may be associated with malar rash, subacute cutaneous lesions, photosensitivity,
arthritis, serositis, and thrombosis. The prevalence of ant-RNP was 13%(28).
Cervera R, Khamashta MA, Font J, et al.observed that patients with  anti
RNP antibodies had a higher incidence of Raynaud's phenomenon, myositis and
lymphadenopathy. Anti-Sm antibodies occurred in 10% of patients and was
more prevalent in those with oral ulcers and myositis, but less in those with
sicca syndrome. Anti-Ro(SSA) positive patients, have detected that
approximately 90% of their patients are photosensitive.
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While renal disease is an uncommon finding in anti Ro(SSA) antibody
positive patients, it does occur. One study, performing classic acid elution
methodologies upon kidneys obtained at autopsy, has demonstrated, in two anti-
Ro(SSA) positive patients, an enriched concentra tion of anti-Ro(SSA)
antibodies in the kidneys. This has been interpreted as indicating a direct role of
these antibodies, most likely in the form of immune complexes in the
pathogenesis of the renal disease. There is also evidence to indicate that anti-Ro
pa tients, in the absence of anti-La(SSB) antibodies, may be more susceptible to
renal disease.
Patients with  RNP antibodies seldom develop diffuse proliferative
glomerulonephritis, psychosis, or seizures; these abnormalities are a major
source of morbidity and mortality in SLE(101).Patients with RNP antibodies
nearly always have an early development of Raynaud phenomenon and a nail
fold capillary pattern that is the same as in Scl but different from classical
SLE(102).The Raynaud phenomenon only occurs in about 25 percent of patients
with classical SLE.Patients with  RNP antibodies are more likely to develop
pulmonary hypertension than patients with classical SLE or Scl. Pulmonary
hypertension is the major cause of death in MCTD(104).Patients with  RNP
antibodies are more likely than SLE patients to be rheumatoid factor positive
and develop an erosive arthritis(103)
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The ENA ELISA used in this study is becoming the most widely used
method not only for routine screening but also for detection of specific ENA.
Thus this study emphasises  the role of Anti ENA antibody testing in the
diagnosis of connective tissue disorders .
.
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7. SUMMARY
This study was conducted for a period of 1 year from April 2016 to
March 2017. The  study population  mainly consisted of 100 patients , attending
Rheumatology department ,Tirunelveli  Medical college hospital ,Tirunelveli.
50 patients  had signs and symptoms related to connective tissue disorders and
were ANA positive. Another 50 patients had no signs and symptoms related to
CTD and were ANA negative . The age group studied  was 15-65 years .Both
sexes were included.
 The mean age among cases and controls was 36 years.
 Out of 100  patients tested, 28 (56%) of ANA positive patients and 3 (6
%) among control group were found to be positive for extractable nuclear
antibodies by ENA screening ELISA
 Among ENA positive subjects most common age group was 30-39 years
that is  38.7% were in this age group
 Extractable Nuclear Antibodies were found most predominantly in
females (28 out of 31) 90.3% compared to males (3 out of 31 ) 9.7%
 Subjects were most commonly affected with skin rash (50%) and bone
involvement (70%) . Lung (18%) and kidneys (10%) were less commonly
affected
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 Sensitivity of the ENA screening ELISA was 56% ,Specificity of the
test was 94% ,Positive predictive value  90.3%,and Negative predictive
value  68.1%
 Among the  31 ENA  positive subjects SSA  was identified in 17 (54%) ,
SSB in  6 (19%), Sm in 16 ( 51%) , RNP/Sm  in 18 ( 58%) , Scl-70 in 4
( 12 %)  patients .
 In our study 20 patients had a clinical diagnosis of SLE,5 had MCTD,3
patients had systemic sclerosis and another 3 had Sjogrens syndrome. 19
had other CTDs.
 Among the 20  SLE patients, 15 had  SSA,    6 had SSB, 12 had  Sm ,11
had RNP/Sm ,and 1 patient had  Scl-70.
 In the 5 MCTD patients , 3 were positive with Sm,and  5 were RNP/Sm
positive.
 In the 3 Systemic sclerosis patients ,1 was positive with SSA , 1 was
positive RNP/Sm, and 2 were positive with Scl-70.
 Among  the 3 patients  with Sjogrens syndrome, 1 was positive with
SSA,1 was positive with Sm and 1 was positive RNP/Sm and 1 with Scl-
70
 The clinical symptoms of the  31 positive ENA subjects was analysed
which showed the following results .
 Skin rash was present in 13 SSA positive subjets and 12 RNP/Sm
positive subjects
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 Bone involvement was noted in 11 SSA positive subjects and 12
RNP/Sm  positive subjects
 Lungs involvement was seen  in 4 SSA positive and 3 RNP.Sm
positive subjects
 Kidney involvement present in 2 SSA positive subjects , 3
RNP/Sm positive subjects  and 2 Scl-70 posotive subjects
 Bone involvement was present in 12 SSA positive subjects and 13
RNP/Sm positive subjects
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8.CONCLUSION
Autoimmune connective tissue diseases are rare group of diseases with
significant impact on patient’s quality of life and socioeconomic aspects.
Antinuclear antibody testing is the gold standard diagnostic tool in CTDs. But
its role as disease activity and prognostic marker is less understood. This study
has ventured to analyze the correlation of ANA profile with disease activity and
prognosis.
ANA testing may provide important data for an upcoming rheumatic
disease, be valuable in the diagnosis and prognosis prediction.A positive ANA
test is important only in conjunction with clinical evaluation and in the absence
of symptoms and signs of a CTD; a positive ANA test only confounds the
diagnosis. A positive ANA test can also be seen in healthy individuals,
particularly the elderly or in a wide range of diseases other than CTD, where it
has no diagnostic or prognostic value.
Antibodies against extractable nuclear antigens (ENAs) are useful
diagnostic markers for various autoimmune connective tissue diseases. The
antibodies can be identified by either counter immunoelectrophoresis (CIE) or
immunoblotting. These techniques, however, are timeconsuming, technically
demanding, and do not provide for fast turnaround times. Over the last few
years, alternative techniques such as ELISA and dot blot (DB) have been
introduced
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ELISA evaluated in this study has the advantage over the other
techniques is that it enables the detection of antibodies with additional
specificities. Its major advantages are its lower price and the fast and
simultaneous detection of different autoantibodies in a single serum. In this
study anti  ENA antibodies were found in  31  ANA positive patients . In
conclusion, ENA ELISA  is a valid method for the simultaneous detection of
various autoantibodies in autoimmune connective tissue disorder.
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1ABBREVIATIONS
ACR – American college of Rheumatology
AIRE – Autoimmune regulator
ANA – Antinuclear antibody
APC – Antigen presenting cell
APS – Antiphospholipid syndrome
BAFF – B-cell activating factor
CCLE – Chronic cutaneous lupus erythematosus
CRP – C- Reactive protein
CTD – Connective tissue disease
CTGF – Connective tissue growth factor
CTLA-4 – Cytotoxic T-Lymphocyte associated protein 4
DC – Dendritic cell
DLE – Discoid lupus erythematosus
DM – Dermatomyositis
EBV – Epstein Barr virus
ELISA – Enzyme linked immunosorbent assay
2ESR – Erythrocyte sedimentation rate
HLA – Human leukocyte antigen
HSP – Heat shock protein
IFN-α – Interferon α
IIF – Indirect immunofluorescence
IL – Interleukin
ILD – Interstitial lung disease
KCS – Keratoconjunctivitis sicca
MCTD – Mixed connective tissue disease
MHC – Major histocompatibility complex
PCNA – Proliferating cell nuclear antigen
PD 1 – Programmed cell death protein 1
PHA – Phytohaemagglutinin
PM – Polymyositis
PTPN 22 – Protein tyrosine phosphatase, non-receptor type 22
RA – Rheumatoid arthritis
RNP – Ribonucleoprotein
3RP – Raynaud’s phenomenon
SCLE – Subcutaneous lupus erythematosus
SLE – Systemic lupus erythematosus
SRC – Scleroderma renal crisis
SS/ SjS – Sjogren’s syndrome
SSc – Systemic sclerosis
TGF-β – Transforming growth factor β
TLR – Toll-like receptor
TNF-α – Tumour necrosis factor α
UCTD – Undifferentiated connective tissue disease
UV – Ultraviolet
VCAM – Vascular cell adhesion protein
4PROFORMA
NAME: AGE:                                        SEX:
OP/IP NO                                                                          OCCUPATION:
ADDRESS:
HISTORY:
1)CUTANEOUS INVOLVEMENT:
Fever/Maculopapularrash/Skinthickening/Otherskinchanges
2)RENAL INVOLVEMENT:Loinpain/Oliguria/Anuria/Haematuria
3)CNS INVOLVEMENT:Haedache/Vomiting/Photophobia/Seizure
4)BONE INVOLVEMENT:Arthralgia/Early morning stiffnes/Swelling/Numbness
5)GASTRO INTESTINAL INVOLVEMENT:Constipation/Diarrhoea/Heartburn
6)RESPIRATORY INVOLVEMENT:cough/dypsnoea/wheeze
7)CARDIAC INVOLVEMENT:chest pain/dyspnoea
OBSTETRIC HISTORY:
MESTRUAL HISTORY:
H/O FAMILY MEMBERS WITH  SIMILAR ILLNESS:
H/O SMOKING/ALCOHOLIC/DRUG INTAKE:
H/O HT/DM/TB/STD:
GENERAL EXAMINATION:
5BUILT :                                                                                 TEMP:
PALLOR:                                                                               WT:
FACIAL BUFFINESS:                                                            HR:
PEDAL EDEMA:                                                                   RR:
CYANOSIS:                                                                           BP:
JAUNDICE:                                                                           ABD DISTENTION:
INVESTIGATIONS
1)TC:
2)DC:
3)HB%:
4)ESR:
5)BLOOD SUGAR:                             UREA:                        CREATININE:
6)HIV STATUS
7)VDRL:
8)THYROID PROFILE:
9)CHEST X-RAY:
10)CT-SCAN:
611)USG:
12)ECHO:
13)URINE ALBUMIN:                             SUGAR:                                        DEPOSIT:
14:CRP:
15)ASO:
16)RA:
17)ANA ELISA:
